The Tata Group, one of the largest companies in India, are now expanding their focus to include diabetes research and development. The group has reportedly made significant advancement in the fields of diabetes and metabolic disorder.
Top executives at Tata Industries said that research is ongoing, and the company are examining potential treatments for diabetes . However, Tata have made it clear that they will not start to manufacture pharmaceuticals . Their focus will be on pharma technology.
The company have not yet fixed a budget or milestones for their diabetes treatment development. Tata made history earlier this year by releasing the world’s smallest car, the Nano, to the Indian market.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…